ADVANCING IMMUNO-ONCOLOGY

Management

President & Chief Executive Officer

Maria Fardis, PhD, MBA

Dr. Fardis joined Iovance as President and Chief Executive Officer, and was appointed to the Company’s Board of Directors, in 2016. Prior to Iovance, Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. Previously, Dr. Fardis worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S., summa cum laude, in Chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

General Counsel

Frederick G. Vogt, PhD, Esq.

Dr. Vogt joined Iovance Biotherapeutics in September of 2016.  He has more than 15 years of experience in the pharmaceutical and biopharmaceutical industries.  Prior to joining Iovance, he practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional, and litigation matters.  Previously he served in numerous scientific, management, and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development.  Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University, and a J.D. from Temple University.  He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania.

Chief Medical Officer

Friedrich Graf Finckenstein, MD

Dr. Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry. Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy. Prior to that, Dr. Graf Finckenstein held multiple clinical leadership roles at Bristol-Meyers Squibb Company, where he worked on an array of products from early clinical development to late stage, including key contributions to the approval of Opdivo® in lung cancer. Dr. Graf Finckenstein has a medical degree from the University of Hamburg in Germany. He holds a German medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute, San Diego Branch, the Children’s Hospital Los Angeles and the University of Hamburg.

Vice President, Finance

Michael C. Swartzburg

Mr. Swartzburg has served as the Company’s Vice President, Finance since March 2018. He has over 25 years of experience in finance in building companies and creating entity value, including participating in over $1 billion of M&A, IPO and financing activities. Prior to Iovance, he provided contracted financial and board of director advisory services to various public and private biotechnology and technology companies. Prior to that, Mr. Swartzburg served roles at Adverum Biotechnologies, Inc., formally known as Avalanche Biotechnologies, Inc., including serving as Vice President, Finance, Controller and Principal Accounting Officer where he was part of the team that led a successful IPO in 2014. Prior to joining Adverum, he served as Vice President, Finance and Corporate Controller for One Medical Group, a healthcare provider and technology company and as the Corporate Controller for MAP Pharmaceuticals, Inc., a publicly held biopharmaceutical company, which was acquired by Allergan, Inc. in 2013. Mr. Swartzburg started his career as a certified public accountant and auditor at Ernst & Young, LLP, in Los Angeles, California. Mr. Swartzburg received his B.S. in Business Administration, with an option in Accounting, at California State University, Northridge